Globally approximately 400,000 people are diagnosed with bladder cancer each year, with it being the fifth most common cancer in the UK and it having the highest recurrence rate of any malignancy. In Europe and the United states there are approximately 6 million tests performed each year to diagnose bladder cancer, with many of these procedures being highly invasive.
Patients are referred to the urology clinic with blood in their urine and/or with pain, urgency or increased frequency of urination. Only about 10% of these patients will have cancer but currently almost all undergo invasive, uncomfortable and expensive internal examination by cystoscopy, the current gold standard test for the diagnosis of bladder cancer.
UroSens’ urine-based test will be used to stratify those patients whose symptoms are caused by non-life threatening conditions thereby eliminating the time and expense involved in examining all patients by the current procedures.
Bladder cancer has a very high recurrence rate; approximately 65% of patients will suffer a relapse. Following treatment, patients must return to the clinic for regular re-testing by cystoscopy. The regime varies according to the grade of the patients’ cancer but typically involves 3-monthly examinations for the first few years. Using UroSens’ test, surveillance testing can be moved back to primary care, with patients only being required to leave a urine sample with their general practitioner.
The MCM5 test fulfils the requirements of a screening tool. It is cost-effective and non-invasive, making it easy for the over 50s to have an annual test at their GP’s surgery. This will detect early stage disease and allow immediate treatment leading to improved patient outcomes and significant downstream savings for healthcare providers.
The test will first be used in urology clinics and later in primary care.